Brought to you by 
Biovitrum completes its IPO; brings in SEK770mm
02 Nov 2006
Executive Summary
Biovitrum (developing compounds for conditions that include obesity, diabetes, inflammation, and blood diseases) has raised SEK770mm ($105.2mm) with the initial public offering of 7.7mm common shares (including the overallotment) priced at SEK100 each.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biovitrum completes its IPO; brings in SEK770mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice